These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21098256)

  • 1. Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
    Ma SW; Li YY; Zhang GW; Huang X; Sun J; Li C; Abbott WG; Hou JL
    Antimicrob Agents Chemother; 2011 Feb; 55(2):888-94. PubMed ID: 21098256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
    Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
    Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
    Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
    Liang J; Han T; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
    Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
    Lv G; Ying L; Ma WJ; Jin X; Zheng L; Li L; Yang Y
    Virol J; 2010 Aug; 7():207. PubMed ID: 20807412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
    Hou FQ; Wu XJ; Wang Y; Chen J; Liu YZ; Ren YY; Song G; Ding YP; Yu M; Wang GQ
    J Viral Hepat; 2013 Apr; 20 Suppl 1():18-26. PubMed ID: 23458521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Tillmann HL; McHutchison JG
    N Engl J Med; 2008 Apr; 358(14):1517; author reply 1517-8. PubMed ID: 18385505
    [No Abstract]   [Full Text] [Related]  

  • 14. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
    J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
    Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
    Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
    Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
    J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
    Nan XP; Zhang Y; Yu HT; Sun RL; Peng MJ; Li Y; Su WJ; Lian JQ; Wang JP; Bai XF
    Viral Immunol; 2012 Feb; 25(1):21-8. PubMed ID: 22233255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
    Lai Q; Ma S; Ge J; Huang Z; Huang X; Jiang X; Li Y; Zhang M; Zhang X; Sun J; Abbott WG; Hou J
    PLoS One; 2014; 9(2):e88475. PubMed ID: 24551107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telbivudine in the treatment of chronic hepatitis B.
    Nash K
    Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.